Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI by López-Giménez, Juan F. et al.
For Peer Review
 
 
 
1
 
Multiple conformations of 5-HT2A and 5-HT2C receptors in rat 
brain. An autoradiographic study with [
125
I](±)DOI 
 
 
Juan F. López-Giménez
1
, M. Teresa Vilaró
3
 , José M. Palacios
2
 and Guadalupe Mengod
3
. 
 
1
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC-CSIC, UC), Santander, 
Spain. 
 
2
Frontera Biotechnology, Barcelona, Spain 
 
3
Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC, IDIBAPS, 
CIBERNED), Barcelona, Spain. 
 
 
 
Correspondence to: Guadalupe Mengod, tel.: 34 933 63 83 23, fax: 34 933 63 83 01, e-
mail: guadalupe.mengod@iibb.csic.es 
Page 1 of 30
Physiologisches Institut, Universit?t Wuerzburg, Roentgenring 9,  97970 Wuerzburg, Germany. Phone: +49 931 312639
Experimental Brain Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
 
2
Summary 
Earlier autoradiographic studies with the 5-HT2 receptor agonist [
125
I](±)DOI in 
human brain showed unexpected biphasic competition curves for various 5-HT2A 
antagonists. We have performed similar studies in rat brain regions with selective 5-HT2A 
(M100907) and 5-HT2C (SB242084) antagonists together with ketanserin and mesulergine. 
The effect of GTP analogs on antagonist competition was also studied. Increasing 
concentrations of Gpp(NH)p or GTPγS resulted in a maximal inhibition of [
125
I](±)DOI 
specific binding of approximately 50%. M100907 competed biphasically in all regions. In 
presence of 100µM Gpp(NH)p, M100907 still displaced biphasically the remaining 
[
125
I](±)DOI binding. Ketanserin showed biphasic curves in some regions, and monophasic 
curves in others. In the latter, Gpp(NH)p evidenced an additional high affinity site. 
SB242084 competed biphasically in brainstem nuclei and monophasically in the other 
regions. In most areas, SB242084 affinities were not notably altered by Gpp(NH)p. 
Mesulergine competed monophasically in all regions without alteration by Gpp(NH)p.  
These results conform with the extended ternary complex model of receptor action: 
receptor exist as an equilibrium of multiple conformations, i.e., ground (R), partly 
activated (R*) and activated G-protein coupled (R*G) conformation/s. Thus, [
125
I](±)DOI 
would label multiple conformations of both 5-HT2A and 5-HT2C receptors in rat brain and 
M100907 and ketanserin would recognize these conformations with different affinities. 
 
Keywords: Receptor autoradiography, G-protein coupling, inverse agonist 
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Introduction 
 The group of serotonin type 2 receptors (5-HT2 receptors) is comprised by three 
subtypes: 5-HT2A, 5-HT2B and 5-HT2C receptors. They share several characteristics in 
common such as some degree of sequence homology as well as the stimulation of the same 
primary effector system (phospholipase C, PLC) via G-protein coupling (Hoyer et al. 1994; 
Barnes and Sharp 1999). In addition, the 5-HT2 receptor family is peculiar when compared 
to other G-protein coupled receptors because they are downregulated upon antagonist 
treatments in some cases (Roth et al. 1998; Yadav et al. 2011). As a consequence of this 
structural homology, the pharmacological characterisation of each of these receptors has 
been difficult due to the lack of selective drugs that really differentiate among them 
(Baxter et al. 1995). Since the first description of 5-HT2 receptors by means of radioligand 
techniques (Peroutka and Snyder 1979), several radiolabeled drugs have been used to study 
these receptors. Some of them are phenylalkylamines such as DOB (4-bromo-2,5-
dimethoxyphenyl-isopropilamine) and DOI (4-iodo-2,5-dimethoxyphenyl-isopropilamine) 
in their radiochemical forms [
3
H]DOB and [
125
I]DOI respectively. These compounds 
behave as agonists at 5-HT2 receptors and present similar affinities for the three different 
subtypes (Nelson et al. 1999; Knight et al. 2004). Certain studies performed with both 
radioligands led to the hypothesis of the existence of different subtypes of 5-HT2A 
receptors in different mammalian species (McKenna and Peroutka 1989)(Pierce and 
Peroutka 1989). In contrast, other studies carried out in cell lines heterologously expressing 
either rat 5-HT2A or human 5-HT2A receptors demonstrated that the different binding sites 
labelled by [
125
I]DOI and [
3
H]DOB respectively corresponded to multiple states of a same 
receptor and not multiple receptor subtypes (Branchek et al. 1990) (Teitler et al. 1990) , 
being these multiple states a consequence of the receptor coupling to G-proteins. Later 
studies performed with [
125
I]DOI in native tissues by means of receptor autoradiography 
described that several antagonists (ketanserin, spiperone and cinanserin) displayed biphasic 
curves when displacing [
125
I]DOI binding from some human brain regions (Waeber and 
Palacios 1994). These two binding site populations recognised by the agonist radioligand 
and some antagonist competitors did not correspond clearly to different receptor subtypes, 
so it was hypothesised that allosteric phenomena were taking place. Subsequently, more 
selective antagonists for 5-HT2A and 5-HT2C receptors were synthesized, among them 
M100907 or volinanserin (formerly MDL100,907) and SB242084 respectively (Kehne et 
al. 1996; Kennett et al. 1997). We extended previous studies performed in human brain by 
including these more selective compounds as competitors and by using a permanent cell 
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line heterologously expressing human 5-HT2A receptors (Lopez-Gimenez et al. 2001); 
competition assays under these new experimental conditions with selective antagonists for 
5-HT2A receptors, i.e. ketanserin and M100907, resulted again in curves displaying two 
binding sites regardless the sample origin (native tissue or cultured cells). More recently, 
the functional characterisation of 5-HT2A receptors expressed in CHO cells in parallel with 
radioligand binding competition assays led to the proposal of a new model of multiple 
active interconvertible conformations of dimeric receptors to explain this biphasic 
component observed for some antagonists (Brea et al. 2009). 
 The aims of the present work were to further analyze the atypical biphasic profile of 
ketanserin when displacing [
125
I]DOI binding in different rat brain areas, and at the same 
time to examine the pharmacological behaviour of mesulergine, M100907 and SB242084 
in equivalent competition experiments. In an attempt to elucidate the nature of the 
heterogeneous binding sites labelled by [
125
I]DOI in rat brain, the effect of non-
hydrolisable GTP analogues on [
125
I]DOI binding and antagonist displacements was also 
considered.  
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Methods 
 
Animal brains 
 Male Wistar rats (200-300 g) were purchased from Iffa Credo (Lyon, France). The 
animals were killed by decapitation and the brains were removed quickly and frozen on dry 
ice. Animal care followed the spanish legislation on "Protection of Animals Used in 
Experimental and Other Scientific Purposes", in agreement with the E.E.C. regulations on 
the care of laboratory animals (O.J. of E.C. L358/1 18/12/1986). Tissue sections, 14 µm 
thick, were cut using a microtome-cryostat (Microm HM500-OM, Walldorf, Germany), 
thaw-mounted onto APTS (3-aminopropyltriethoxysilane, Sigma, St. Louis, Mo, USA) 
coated slides, and kept at -20°C until use. 
 
Receptor autoradiography 
 [
3
H]mesulergine (82.0 Ci/mmol) and [
125
I](±)DOI (2200 Ci/mmol) were purchased 
from Amersham (UK) and DuPont NEN (Boston, MA) respectively. Ritanserin, 
mesulergine, ketanserin and mianserin were purchased from Research Biochemical 
International (Natick, MA). Gpp(NH)p (5'-guanylylimidodiphosphate), GTPγS (guanosine-
5'-O-(3-thio)triphosphate), 5-HT (5-Hydroxytryptamine) and (±)DOI ((±)-1-(2,5-
dimethoxy-4-iodophenyl)-2-aminopropane) were purchased from Sigma (UK). 
MDL100,907 ((R)-(+)-4-[1-Hydroxy-1(2,3-dimethoxyphenyl)methyl]N-2-4-
fluorophenylethyl)piperidine) was a generous gift from Dr. M. Galvan (Marion Merrell 
Dow, Strasbourg, France). SB242084 (6-Chloro-5-methyl-1-[6-(2-methylpyridin-3-
yloxy)pyridin-3-yl-carbamoyl]indoline) was kindly provided by Smithkline Beecham 
Pharmaceuticals (UK). 
[
125
I](±)DOI saturation experiments were carried out within the 0-1.5 nM 
concentration range to determine total binding. Non-specific binding was determined at 
three different radioligand concentrations, and the values obtained were used to generate a 
linear regression curve. To obtain specific binding for each radioligand concentration, the 
calculated value of non-specific binding was subtracted from the corresponding total 
binding value. In competition experiments, [
125
I](±)DOI was used at a concentration 
between 100 and 150 pM. Non-specific binding in saturation and competition experiments 
was defined as that remaining in the presence of 10
-5
M ritanserin. Experimental procedures 
were as described (McKenna and Peroutka 1989) with some modifications: cryostat tissue 
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sections were air dried, pre-incubated for 30 min at room temperature in 50 mM Tris-HCl 
pH 7.4, 0.1% ascorbate, 4mM CaCl2, and incubated in the presence of radioligand in the 
same buffer during 60 min at room temperature. After incubation, tissue sections were 
washed during 10 min twice in ice cold buffer, dipped in distilled ice cold water and dried 
rapidly under a cold air stream. Tissues were exposed to tritium-sensitive film (Hyperfilm-
3
H, Amersham, UK) together with plastic 
125
I-standards (
125
I-microscales, Amersham, UK) 
for a period of time between 2 and 5 days.  
In saturation studies, [
3
H]mesulergine was used at increasing concentrations 
between 0-5 nM in rat choroid plexus to obtain values of total binding. Non-specific 
binding and specific binding was determined as for [
125
I](±)DOI saturation experiments. In 
competition studies [
3
H]mesulergine was used at a concentration of 0.5 nM. Non-specific 
binding in saturation and competition experiments was defined as that remaining in the 
presence of in the presence of 10
-5
M mianserin. The incubation protocol for 
[
3
H]mesulergine was as described previously (Pazos and Palacios 1985). Briefly, cryostat 
tissue sections were air dried, pre-incubated for 15 min at room temperature in 50 mM 
Tris-HCl pH 7.6, 10 mM, and incubated in the presence of radioligand in the same buffer 
during 120 min at room temperature. After incubation, tissue sections were washed for 10 
min twice in ice cold buffer, dipped in distilled ice cold water and dried rapidly under a 
cold air stream. Tissues were exposed to tritium-sensitive film (Hyperfilm-
3
H, Amersham, 
UK) together with plastic 
3
H-standards (
3
H-microscales, Amersham, UK) for 1 week. 
Quantitative analysis of the autoradiograms obtained with both radioligands was done with 
a computerized image analysis system (MCID M4, St. Catharines, Ontario, Canada). 
 
Data analysis 
 Estimates of binding parameters (Kd, Bmax, IC50 and Hill slope) were derived with 
the GraphPad Prism software (GraphPad Software Inc, San Diego, CA) from the data 
obtained after quantification of the autoradiograms generated in saturation and competition 
experiments. The program calculated Ki values according to the Cheng-Prusoff equation 
(Cheng and Prusoff 1973) using the IC50 previously determined in competition 
experiments, the mean of the Kd for the radioligand in the different brain regions obtained 
in saturation experiments and the concentration of free radioligand used in competition 
experiments. 
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Results 
 
Pharmacological characterisation of  [
125
I](±)DOI binding sites 
 Saturation experiments performed with [
125
I](±)DOI in different rat brain areas 
resulted in affinity constants (Kd) in the subnanomolar or low nanomolar range (Table 1; 
Fig. 1), being frontal cortex, claustrum and choroid plexus the brain areas that presented 
the highest densities of binding sites. Inhibition experiments with Gpp(NH)p, a non-
hydrolisable GTP analogue, were carried out to examine the effect of receptor/G-protein 
uncoupling on [
125
I](±)DOI binding. Figure 2A displays inhibition curves obtained in two 
representative regions, frontal cortex and choroid plexus, with pIC50 values of 6.69±0.19 
and 6.72±0.35 respectively (mean±s.e.m., n=4 animals). In all the regions examined, a 
maximum of approximately 50% of specific binding was inhibited. The effect of GTPγS, 
another GTP analogue, on [
125
I](±)DOI binding was also studied resulting in inhibition 
parameters similar to those of Gpp(NH)p: pIC50 7.55±0.18 in frontal cortex and 6.85±0.24 
in choroid plexus (mean±s.e.m., n=4 animals) with approximately 50% of maximal 
inhibition of specific binding in both brain areas (Fig. 2B). For subsequent experiments, 
Gpp(NH)p at a concentration of 100 µM was used to uncouple receptors from G-proteins.  
Competition studies were carried out at a [
125
I](±)DOI concentration between 100-
150 pM. Non-specific binding was determined with 10
-5
M ritanserin, resulting in a 
remaining autoradiographic signal hardly distinguishable from film background (Fig. 3B). 
Four antagonists, M100907, ketanserin, SB242084 and mesulergine, were competed 
against [
125
I](±)DOI in absence or presence of 100µM Gpp(NH)p. Addition of Gpp(NH)p 
resulted in a reduction of approximately 50% of the specific binding observed in absence 
of competing drug. Inhibition parameters obtained in competition experiments are 
summarised in Table 2, and Figure 4 displays inhibition curves for three representative rat 
brain regions. When [
125
I](±)DOI binding was inhibited by M100907, the data points were 
best fitted by a two site model in the different rat brain regions considered in this study. 
The high affinity site was in the low nanomolar range, except in the choroid plexus where 
this high affinity site displayed 100-fold lower affinity than in the rest of the regions. In 
presence of Gpp(NH)p, M100907 still displaced the remaining [
125
I](±)DOI binding sites 
in a biphasic manner in the majority of brain regions, with affinities about two orders of 
magnitude lower than those observed without the GTP analogue. In some regions (choroid 
plexus, olfactory tubercle and claustrum) a single binding site was observed in presence of 
Page 7 of 30
Physiologisches Institut, Universit?t Wuerzburg, Roentgenring 9,  97970 Wuerzburg, Germany. Phone: +49 931 312639
Experimental Brain Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
 
8
Gpp(NH)p, with an affinity similar to the low affinity site observed in absence of 
Gpp(NH)p (Table 2). 
The competition of [
125
I](±)DOI with ketanserin resulted in monophasic inhibition 
curves in forebrain regions (frontal cortex, caudate-putamen, nucleus accumbens, olfactory 
tubercle and claustrum) and in biphasic curves in the analysed brainstem nuclei (dorsal 
motor nucleus of vagus, hypoglossal nucleus and facial nucleus). The choroid plexus also 
presented two binding site populations, with affinity constants similar to those observed in 
the brainstem nuclei. However, the percentage of high affinity sites was much lower in 
choroid plexus (Table 2). The presence of Gpp(NH)p in the incubation medium revealed 
an additional high affinity site in the forebrain areas (Table 2; Fig. 5), whereas no 
significant changes were observed in the affinity constants of the two sites detected in 
brainstem nuclei and choroid plexus. In this latter case, however, Gpp(NH)p induced a 
marked increase (from 20% to 60% approximately) in the percentage of high affinity sites 
(Table 2). 
SB242084 presented monophasic displacement curves against [
125
I](±)DOI in the 
different rat forebrain areas studied as well as in choroid plexus, although the affinity in 
this structure was about two orders of magnitude higher. On the other hand, data points 
corresponding to the brainstem nuclei were best fitted by a two site model (Table 2, Fig. 
4), with the high affinity site similar to the one observed in choroid plexus, and the low 
affinity site similar to the one observed in forebrain regions. In the majority of the rat brain 
regions, presence of Gpp(NH)p did not induce notable changes in the affinities and relative 
proportions of high and low affinity sites. However, there were two regions, nucleus 
accumbens and claustrum, where significant changes were observed: in both regions an 
additional high affinity site was observed that accounted for 30% approximately of the 
total [
125
I](±)DOI binding sites in presence of Gpp(NH)p (Table 2; Fig. 5). 
Mesulergine was the only antagonist compound that presented a single high affinity 
site in all the rat brain regions analysed which was not modified by the presence of 
Gpp(NH)p (Table 2, Fig.5). 
 
[
3
H]mesulergine autoradiography studies. 
 Saturation experiments in absence or presence of 100µM Gpp(NH)p were 
performed with rat brain sections containing choroid plexus resulting in no significant 
differences either in Kd values (0.61 ± 0.11 nM versus 1.05 ± 0.26 nM) as in maximum 
specific binding sites (836.20 ± 40.9 fmol/mg versus 924.30 ± 79.9 fmol/mg). Competition 
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9
experiments against [
3
H]mesulergine in choroid plexus were carried out with the 
antagonists M100907, ketanserin, SB242084 and mesulergine, and with the agonists 5-HT 
and (±)DOI. Inhibition constants for each compound are summarised in Table 3. All the 
competitors displayed monophasic displacement curves, being SB242084 and M100907 
the drugs that presented the highest and lowest affinity respectively for [
3
H]mesulergine 
binding sites in rat choroid plexus. The presence of Gpp(NH)p did not change the 
inhibition parameters for any competitor drug. As expected from the results from 
saturation experiments, addition of 100µM Gpp(NH)p did not alter total [
3
H]mesulergine 
binding in absence of competitor drugs. 
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Discussion 
 The aim of the present work was to further explore into the nature of the previously 
observed biphasic profile of ketanserin and other 5-HT2 compounds when displacing 
[
125
I]DOI binding in autoradiographic studies (Waeber and Palacios 1994; Lopez-Gimenez 
et al. 2001). For this purpose, we have expanded the study in rat brain by including two 
more selective antagonists (M100907 and SB242084) together with two more classical 
compounds (ketanserin and mesulergine) already used in the aforementioned report. In 
addition, the role of receptor/G-protein coupling in this  atypical pharmacological profile 
was also investigated by examining the effect of non-hydrolisable GTP analogues on 
[
125
I]DOI binding and antagonist displacements. The results obtained from the present 
series of experiments indicate that the biphasic profile previously shown for ketanserin is 
also shared by the more selective 5-HT2A antagonist M100907 and this happens both at 5-
HT2A and 5-HT2C receptors. Furthermore, the presence of a non-hydrolizable GTP 
analogue (Gpp(NH)p) altered the affinities for [
125
I]DOI binding sites displayed by 
ketanserine, M100907, and SB242084, suggesting the lack of true silent antagonism of 
these compounds.  
After the first description of [
125
I](±)DOI as a radioligand for autoradiography 
(McKenna et al. 1987), it was later more extensively characterised for the autoradiographic 
visualisation of 5-HT2A and 5-HT2C receptors in rat brain (Appel et al. 1990). Our present 
results concerning the affinity constant of [
125
I](±)DOI for its binding sites in rat brain (Kd 
in the low nanomolar range) agree well with those described previously in 
autoradiographic studies (McKenna et al. 1989) or in binding studies using rat brain 
homogenates (Johnson et al. 1987) (McKenna et al. 1987; Glennon et al. 1988). Given the 
ability of [
125
I](±)DOI to label both 5-HT2A and 5-HT2C receptors,  it is first of all 
necessary to establish the nature of the sites labelled by this radioligand in the different rat 
brain regions considered in the present study. Very likely, the binding sites labelled by 
[
125
I](±)DOI correspond to 5-HT2A receptors predominantly in rat forebrain regions, to 5-
HT2C receptors in rat choroid plexus and to both receptor subtypes in rat brainstem nuclei. 
This is supported by several experimental evidences: 1) [
125
I](±)DOI at the concentration 
used in competition experiments (0.10-0.15 nM) does not label other neurotransmitter 
receptors different from the 5-HT2 receptor family in rat brain (Appel et al. 1990). 2) The 
possibility that [
125
I](±)DOI at the concentration used labelled 5-HT2B receptors in rat brain 
is very unlikely since it seems that this receptor subtype is not present to a significant 
extent in the brain of another rodent species (Loric et al. 1992) and no 5-HT2B receptor 
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mRNA could be detected in rat brain by means of in situ hybridisation techniques 
(unpublished observations). 3) Visualisation of choroid plexus by receptor autoradiography 
in mouse brain is possible by using [
125
I](±)DOI, [
3
H]5-HT or [
3
H]mesulergine as 
radioligands. The complete absence of autoradiographic signal in choroid plexus from 
genetically engineered mice devoid of expression of 5-HT2C receptors indicates that this is 
the only receptor labelled by these radiochemicals in this particular structure of rodent 
brain (Lopez-Gimenez et al. 2002). 4) The pharmacological data obtained in the present 
study with SB242084, a 5-HT2C receptor selective compound (Kennett et al. 1997), support 
the 5-HT2A and/or 5-HT2C receptor nature of these [
125
I](±)DOI binding sites. Thus, 
SB242084 showed monophasic displacement curves in the analyzed forebrain structures 
with a pKi close to that described for human 5-HT2A receptors expressed in permanent cell 
lines (pKi ≈ 6.8), whereas in rat choroid plexus it also presented a single site with a pKi 
very similar to that described for human 5-HT2C receptors expressed in permanent cell 
lines (pKi ≈ 9.0) (Kennett et al. 1997). In addition, SB242084 displayed biphasic 
competition curves in rat brainstem motor nuclei differentiating two binding site 
populations: the high affinity site presented an affinity constant very similar to that found 
in choroid plexus, whereas the low affinity site presented an affinity constant similar to 
that found in forebrain structures. These results agree with the presence of both 5-HT2A and 
5-HT2C receptors in the rat facial, hypoglossal and motor nucleus of the vagus, where the 
presence of encoding mRNA for both receptors has previously been demonstrated 
(Pompeiano et al. 1994; Wright et al. 1995). Although the presence of mRNA for both 5-
HT2A and 5-HT2C receptors has been described also in some of the forebrain nuclei 
considered in the present study as models of 5-HT2A-enriched regions (e.g. claustrum, 
accumbens, olfactory tubercle (Pompeiano et al. 1994) (Wright et al. 1995), the presence 
of a relevant population of [
125
I](±)DOI-labeled 5-HT2C receptors in these brain regions is 
unlikely, since had it existed, it would have been detected most probably by SB242084. 
These findings with SB242084 corroborate the selectivity of this compound for 5-HT2C 
versus 5-HT2A receptors in rat brain, and indicate its suitability for the pharmacological 
characterisation of these receptors. 
At variance with SB242084, mesulergine displaced [
125
I](±)DOI binding sites in a 
monophasic manner presenting the same inhibition constant in all the rat brain regions 
analysed. This was an expected observation since mesulergine presents very similar 
affinities for both receptor subtypes in rat brain and therefore does not differentiate 
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between 5-HT2A and 5-HT2C receptors in this species, in contrast to what is observed in pig 
and human brain (Hoyer et al. 1986).  
 The pharmacological profile obtained with ketanserin in rat forebrain structures, 
where a single high affinity site was observed, agrees with the affinity of this compound 
for 5-HT2A receptors. These results differ from those described in human brain using the 
same radioligand and competitor: in this case ketanserin displayed biphasic curves when 
inhibiting [
125
I](±)DOI binding sites in cortex, claustrum and striatum (Waeber and 
Palacios 1994; Lopez-Gimenez et al. 2001). On the other hand, the biphasic competition 
curves observed with ketanserin in rat brainstem nuclei most likely correspond to the 
inhibition of [
125
I](±)DOI labelling of 5-HT2A and 5-HT2C receptors by ketanserin (high 
and low affinity sites respectively). In contrast, ketanserin presented an unexpected high 
affinity site in choroid plexus in addition to the lower affinity site which is in accordance 
with 5-HT2C receptors. Unexpectedly also, competition binding assays performed with the 
more selective 5-HT2A receptor antagonist M100907, resulted in biphasic displacement 
curves in all the regions analysed, and independently, therefore, whether [
125
I](±)DOI 
labelling corresponded to 5-HT2A receptors predominantly (forebrain), to 5-HT2C receptors 
(choroid plexus) or to both simultaneously (brainstem nuclei). 
In an attempt to further analyse the nature of the different [
125
I](±)DOI binding sites 
detected by the antagonists, competition experiments in the presence of GppNHp, a non-
hydrolizable analogue of GTP were conducted. Previous studies (Appel et al. 1990) have 
analyzed the effect of GTP analogues (GTPγS and Gpp(NH)p) on [
125
I](±)DOI binding. 
The results obtained in that study concerning inhibition constants (IC50) as well as the 
percentage of inhibition of [
125
I](±)DOI specific binding at the maximal concentration of 
GTP analogue (about 55%), were very similar to the present ones for both analogues. 
There is, however, a point of disagreement between both studies regarding the effect of 
GTP analogues on [
125
I](±)DOI binding in rat brain. This discrepancy, the reason for which 
is unclear at present, consists in the image that Appel and co-workers showed in their 
report where [
125
I](±)DOI autoradiographic signal is completely inhibited by 100 nM 
GTPγS, in contrast with their own quantitative data and with our present results (see Fig. 
3D). Other studies performed with homogenates of pig choroid plexus and rat and human 
cortex (Leonhardt et al. 1992) also described a maximal inhibition by Gpp(NH)p of 55-
60% of specific [
125
I](±)DOI binding. It seems thus evident that GTP analogues, even at 
very high concentrations, are unable to completely inhibit the binding of [
125
I](±)DOI in 
different species. Given that such high concentrations of GTP analogues are thought to 
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completely uncouple receptors from G-proteins, it can be assumed that the remaining 
[
125
I](±)DOI specific binding in presence of 100µM Gpp(NH)p corresponds predominantly 
to uncoupled form/s of the receptors.  
The fact that Gpp(NH)p produces alterations in the pharmacological profile 
obtained for some antagonists suggests that, at the concentration used in competition 
experiments (100-150 pM), [
125
I](±)DOI labels, for both 5-HT2A and 5-HT2C receptors, 
different populations of binding sites whose characteristics depend on the degree of 
receptor/G-protein coupling. When Gpp(NH)p was present during the competition 
experiments, the binding parameters observed for M100907 and ketanserin were altered in 
the majority of the rat brain regions analysed as well as those of SB242084 in claustrum 
and nucleus accumbens. In other words, these antagonists recognized differently the total 
versus the uncoupled population of [
125
I](±)DOI binding sites. Interestingly, this 
characteristic seems to be intrinsic to the primary structure of the receptor and therefore not 
applicable to equivalent receptors in other species. Thus, equivalent studies carried out 
with the human orthologous of 5-HT2A receptors, either from brain native tissue or 
heterologously expressed in cell lines, resulted in a different pharmacological profile, i.e., 
biphasic competition curves were obtained with M100907 and ketanserin whereas 
SB242084 and mesulergine both displayed an unique low affinity binding site; 
additionally, no alteration of binding parameters as a consequence of uncoupling receptor 
to G-proteins by adding GTP analogues was observed (Lopez-Gimenez et al. 2001). 
This atypical pharmacology observed in rat brain for some antagonists as well as 
the effects of Gpp(NH)p on [
125
I](±)DOI-antagonist competition curves may be interpreted 
based on the extended ternary complex model of receptor-G protein interactions 
(Lefkowitz et al. 1993). This model proposes that receptors exist as an equilibrium of 
different states or conformations. Thus, an intermediate or partly activated state/s of the 
receptor (called R*) exists between the resting or ground state (R) and the activated one 
coupled with the G-protein (R*G). Agonists (A) may affect the transition from R to AR*G 
at two different stages. On one hand, presence of the agonist will move the R/R* 
equilibrium towards a stabilization of R*, because it is for this receptor form that the 
agonist has higher affinity. On the other hand, it will also stabilize R*G by binding to this 
complex with higher affinity than to R*. According to this model, the stabilisation of an 
intermediate state (R*) by agonist means that agonist binding in the absence of G-protein 
coupling will not reflect the true ground-state (R) of the receptor (Strange 1998) (for an 
extended review see (Strange 1999)). This model has in fact already been considered to 
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explain several experimental findings involving 5-HT2A and 5-HT2C receptors in artificial 
systems. Thus, the relationship between agonist affinity and efficacy observed for agonists 
at 5-HT2A and 5-HT2C receptors expressed in recombinant systems can be more accurately 
explained in the light of this extended ternary complex model (Egan et al. 2000; Roth et al. 
1997). In a similar manner, the different efficiency to couple to G proteins  described for 
RNA editing isoforms of human 5-HT2C receptors is also compatible with this model 
(Niswender et al., 1999). RNA editing isoforms, differing also in their efficiency to couple 
to G proteins, have also been described for rat 5-HT2C receptors (Burns et al. 1997). 
In our present experimental procedure, where we used an agonist radioligand  
([
125
I](±)DOI) to label 5-HT2A and 5-HT2C receptors in rat brain, we have at least two 
factors that may change the proportions among these different receptor states: first, the 
presence of the radioligand itself, that due to its agonist nature could induce receptor 
conformations and/or, at the same time, select among the different receptor conformations 
present in the system (Kenakin 1995; Strange 1998) and second, the presence of 
Gpp(NH)p that uncouples the receptor from G-protein and can therefore modify the 
equilibrium between R*G, R* and R receptor conformations. With these factors in mind, 
we could conjecture that M100907 is able to distinguish the different isomerisation forms 
of both 5-HT2A and 5-HT2C receptors and ketanserin of 5-HT2C receptors. Furthermore, 
ketanserin (in rat forebrain) and SB242084 (in claustrum and nucleus acumbens) only 
discriminate different forms of 5-HT2A receptors in presence of Gpp(NH)p, i.e. when the 
equilibrium among the various forms was altered by uncoupling receptors from G-proteins. 
In contrast, mesulergine does not distinguish these different [
125
I](±)DOI binding 
site populations when this radioligand labels 5-HT2A or 5-HT2C receptors. The results 
obtained in [
3
H]mesulergine binding assays in rat choroid plexus corroborate this finding 
for 5-HT2C receptors: the lack of effect of Gpp(NH)p on [
3
H]mesulergine binding as well 
as on agonist (5-HT and (±)DOI) displacement suggests that this radioligand labels with 
high affinity all the different receptor states/conformations and that the ground state (R) 
predominates over other conformations of 5-HT2C receptors in choroid plexus. In addition, 
the 100-fold higher Bmax obtained for [
3
H]mesulergine than for [
125
I](±)DOI in this region 
also indicates substantially different proportions of the various receptor conformational 
states in favour of the ground state for which agonists present low affinity. This 
predominance of the R form in the total population of sites labeled by [
3
H]mesulergine 
could be the reason why both agonists (5-HT and (±)DOI) do not discriminate the low 
proportion of high affinity agonist sites also labelled by [
3
H]mesulergine. The same 
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15
argument can be considered to explain the monophasic displacement curves obtained for 
M100907 and ketanserin when competing for [
3
H]mesulergine-binding sites, at variance 
with the biphasic profile observed when these antagonists displaced [
125
I](±)DOI binding 
sites in rat choroid plexus. 
The alterations produced by Gpp(NH)p in the affinity profiles of M100907 (loss of 
affinity) and ketanserin and SB242084 (gain of affinity) when displacing [
125
I](±)DOI 
binding sites conform, according to the extended ternary complex model, to the behaviour 
expected for agonists and inverse agonists respectively. That is, since agonists have higher 
affinity for the coupled state (R*G) of the receptors, the net effect of uncoupling the 
receptor/G-protein complex will be a loss of affinity. On the other hand, inverse agonists 
have higher affinity for the uncoupled, inactive form (R) of the receptor. So, the net effect 
of adding GppNHp will be an increased affinity of the inverse agonist. In fact, inverse 
agonist activity has already been described for ketanserin in artificial systems that 
expressed constitutively active mutant 5-HT2A receptors (Egan et al. 1998) or 
constitutively active native 5-HT2C receptors (Barker et al. 1994; Hartman and Northup 
1996). These two latter studies and others (Westphal and Sanders-Bush 1994) have also 
demonstrated inverse agonism for mesulergine in 5-HT2C receptors, in contrast with our 
present data where no indications of such a behaviour were observed for this compound. 
We have to keep in mind, however, that these results come from different experimental 
systems: artificial (transfected cells) versus native system (rat brain). In the same way, we 
want to stress the point that our results were obtained from receptor binding assays, where 
no direct information is obtained about the possible effect of a given compound on receptor 
activity. Therefore, no absolutely firm conclusions can be drawn on the 
agonist/antagonist/inverse agonist nature of a compound solely on the basis of the effects 
of GppNHp on its affinity for a given receptor. Indeed, no intrinsic activity has been 
described to date for M100907 and SB242084 (Kehne et al. 1996), although for M100907 
an atypical pharmacology analogous to an inverse agonism effect has been observed by 
means of autoradiographic techniques in rabbit brain depending on the presence of Mg
++
 
(Aloyo et al. 1998). Interestingly, studies performed with 5-HT2A receptors with a point 
mutation (F340L) demonstrated that certain agonists were unable to induce second 
messenger stimulation although they still displayed high affinity for the receptor (Roth et 
al. 1997). Concerning the present results, a similar situation could be contemplated for 
M100907, that is, this compound could interact with the receptors in an agonist-like 
manner from the receptor binding viewpoint and at the same time behave as an antagonist 
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concerning the second messenger generation (null intrinsic activity). Nevertheless, it 
should be kept in mind that the aforementioned second messenger studies performed to 
date with M100907 and SB242084 have only measured phosphoinositide hydrolysis 
(phospholipase C activity) and that other second messenger pathways could as well be 
activated by these drugs when they interact with 5-HT2A or 5-HT2C receptors. Such 
pleiotropic behaviour, i.e. activation of two effector systems (phosphoinositide hydrolysis 
and arachidonic acid release) by the same receptor has been reported for both 5-HT2A and 
5-HT2C receptors (Berg et al. 1998). This dual measure approach could help elucidate 
whether these compounds have any efficacy at all at different pathways triggered by 5-
HT2A or 5-HT2C receptors. Other measures of receptor functionality such as [
35
S]GTPγS 
binding (Adlersberg et al. 2000) may also prove useful in determining the efficacy of these 
compounds. 
In conclusion, the present results lend further support to the existence also in native 
tissues of multiple conformations of 5-HT2A and 5-HT2C receptors in accordance with the 
extended ternary complex model of receptor action, and show that some antagonists of the 
5-HT2 receptor family are able to discriminate these multiple receptor 
states/conformations. Fur thermore, the effects of the GTP analogue GppNHp on the 
displacement of [
125
I](±)DOI binding sites by M100907 on one hand and by ketanserin or 
SB242084 on the other hand, suggest that these compounds may not be true silent 
antagonists, but may have some degree of, respectively, positive or negative intrinsic 
activity at native 5-HT2A and 5-HT2C receptors. The present work warrants future 
functional studies to elucidate the true agonist/antagonist/inverse agonist nature of these 
seemingly atypical compounds. 
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Table 1. Binding parameters of [
125
I](±)DOI obtained from saturation experiments at 
different levels of rat brain. Values represent mean±s.e.m of four different animals.  
 Kd Bmax (fmol/mg tissue) 
FCx 
 1.61±0.48 14.82±2.76 
CPu  1.71±0.50   5.95±1.20 
Cl  0.81±0.18 12.12±1.31 
7 0.67±0.28   1.64±0.31 
ChP  0.52±0.13 10.48±1.06 
 
 
Table 2. Affinity constants of several compounds for [
125
I](±)DOI-labelled receptors in 
different rat brain regions in absence or presence of 100 µM Gpp(NH)p. Values represent 
mean±s.e.m of four different animals. 
MDL100,907 -logIC50h -logIC50l pKih pKil % h nH 
FCx 10.07±0.12 8.24±0.16 10.01 8.26 60±5.1 0.52±0.01 
FCx(Gpp(NH)p) 7.98±0.06 5.21±0.41 8.00 5.23 86±2.7 0.79±0.02 
CPu 9.30±0.13 7.05±0.24 9.33 7.07 68±5.0 0.54±0.01 
CPu(Gpp(NH)p) 7.80±0.15 4.85±0.23 7.82 4.87 55±4.3 0.40±0.02 
Acb 9.78±0.27 8.02±0.27 9.81 8.04 47±11.3 0.54±0.01 
Acb(Gpp(NH)p) 7.75±0.11 4.99±0.39 7.77 5.02 75±4.8 0.45±0.01 
Tu 9.05±0.12 7.18±0.46 9.07 7.21 79±7.9 0.64±0.01 
Tu(Gpp(NH)p)  7.58±0.09  7.61  1.00 
Cl 9.64±0.19 7.85±0.27 9.67 7.87 65±8.2 0.50±0.01 
Cl(Gpp(NH)p)  7.71±0.07  7.73  1.00 
10+12 9.13±0.12 6.48±0.28 9.15 6.52 68±4.2 0.47±0.01 
10+12(Gpp(NH)p 7.52±0.15 5.44±0.65 7.52 5.46 78±8.1 0.69±0.01 
7 8.87±0.12 5.99±0.22 8.90 6.02 64±4.0 0.42±0.01 
7(Gpp(NH)p) 7.78±0.39 5.93±0.29 7.81 5.96 42±12.7 0.49±0.01 
ChP 6.98±0.12 5.35±0.65 7.04 5.41 79±9.4 0.77±0.01 
ChP(Gpp(NH)p)  6.26±0.09  6.32  1.00 
SB242084       
FCx  6.79±0.05  6.81  1.00 
FCx(Gpp(NH)p)  6.83±0.07  6.86  1.00 
CPu  6.58±0.06  6.61  1.00 
CPu(Gpp(NH)p)  7.04±0.07  7.06  1.00 
Acb  6.61±0.05  6.63  1.00 
Acb(Gpp(NH)p) 9.78±0.49 6.62±0.14 9.80 6.64 26±5.5 0.50±0.01 
Tu  6.72±0.07  6.74  1.00 
Tu(Gpp(NH)p)  7.00±0.07  7.02  1.00 
Cl  6.87±0.05  6.89  1.00 
Cl(Gpp(NH)p) 8.56±0.44 6.56±0.23 8.58 6.58 35±9.9 0.59±0.01 
10+12 7.70±0.42 6.16±0.23 7.70 6.18 36±15.3 0.67±0.01 
10+12(Gpp(NH)p 8.98±0.18 6.81±0.13 9.00 6.48 40±4.6 0.52±0.01 
7 8.23±0.50 6.22±0.21 8.29 6.24 33±11.1 0.58±0.01 
7(Gpp(NH)p) 9.24±0.42 6.75±0.10 9.26 6.77 21±4.5 0.67±0.02 
ChP 8.61±0.06  8.67   1.00 
ChP(Gpp(NH)p) 8.95±0.16  9.01   1.00 
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Table 2. Continued 
ketanserin -logIC50h -logIC50l pKih pKil % h nH 
FCx  7.85±0.06  7.87  1.00 
FCx(Gpp(NH)p) 9.28±0.12 7.17±0.12 9.30 7.19 55±3.8 0.54±0.01 
CPu  7.96±0.06  7.99  1.00 
CPu(Gpp(NH)p) 9.21±0.21 7.03±0.22 9.23 7.05 56±6.5 0.56 
Acb  7.95±0.07  7.97  1.00 
Acb(Gpp(NH)p) 9.34±0.17 7.18±0.16 9.36 7.21 53±4.4 0.50±0.01 
Tu  7.96±0.06  7.98  1.00 
Tu(Gpp(NH)p) 9.01±0.15 6.82±0.15 9.03 6.85 52±4.4 0.50±0.01 
Cl  7.81±0.08  7.83  1.00 
Cl(Gpp(NH)p) 9.29±0.15 7.03±0.17 9.31 7.05 59±4.6 0.49±0.01 
10+12 8.16±0.21 6.34±0.34 8.19 6.35 60±9.8 0.53±0.01 
10+12(Gpp(NH)p 8.50±0.11 5.51±0.38 8.53 5.53 75±3.9 0.52±0.02 
7 8.16±0.18 6.31±0.52 8.19 6.33 72±10.2 0.60±0.01 
7(Gpp(NH)p) 9.03±0.10 5.89±0.16 9.05 5.91 61±2.9 0.36±0.01 
ChP 8.37±0.55 6.52±0.17 8.43 6.59 23±9.9 0.69±0.01 
ChP(Gpp(NH)p) 8.49±0.22 6.51±0.35 8.55 6.56 61±9.1 0.55±0.01 
mesulergine       
FCx 8.52±0.05  8.54   1.00 
FCx(Gpp(NH)p) 8.45±0.06  8.47   1.00 
CPu 8.43±0.05  8.45   1.00 
CPu(Gpp(NH)p) 8.52±0.08  8.54   1.00 
Acb 8.65±0.05  8.68   1.20±0.01 
Acb(Gpp(NH)p) 8.52±0.07  8.54   1.00 
Tu 8.60±0.07  8.62   1.00 
Tu(Gpp(NH)p) 8.52±0.08  8.54   1.00 
Cl 8.67±0.06  8.70   1.00 
Cl(Gpp(NH)p) 8.53±0.06  8.55   1.00 
10+12 8.55±0.07  8.58   1.00 
10+12(Gpp(NH)p 8.07±0.04  8.09   1.00 
7 8.49±0.06  8.51   1.00 
7(Gpp(NH)p) 8.29±0.06  8.31   1.00 
ChP 8.76±0.07  8.83   1.00 
ChP(Gpp(NH)p) 8.77±0.08  8.83   1.00 
h: high affinity site. l: low affinity site. nH: Hill coefficient. 
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Table 3. Affinity constants of several compounds for [
3
H]mesulergine-labelled receptors 
in rat choroid plexus in absence or presence of 100 µM Gpp(NH)p. Values represent 
mean±s.e.m of four different animals. 
 
 -logIC50 pKi nH 
MDL100,907 6.44±0.08 6.71 1.00 
MDL100,907(Gpp(NH)p) 6.70±0.06 6.98 1.00 
ketanserin 7.07±0.05 7.34 1.00 
ketanserin (Gpp(NH)p) 7.09±0.05 7.37 1.00 
SB242084 8.62±0.06 8.88 1.00 
SB242084(Gpp(NH)p) 8.65±0.04 8.91 1.00 
5-HT 7.87±0.08 8.13 1.00 
5-HT(Gpp(NH)p) 7.74±0.05 7.99 1.00 
(±)DOI 7.44±0.05 7.70 1.00 
(±)DOI(Gpp(NH)p) 7.32±0.05 7.58 1.00 
nH: Hill coefficient. 
 
 
 
 
 
 
Figure 1. Saturation analysis of [
125
I](±)DOI binding to rat frontal cortex (A) and rat choroid plexus (B). 
Each point represents the mean specific binding of four animals. 
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Figure 2. Inhibition curves of [
125
I](±)DOI binding by non-hydrolisable GTP analogues (A: Gpp(NH)p; B: 
GTPγS) in rat frontal cortex (■) and rat choroid plexus (□).Each point represents the mean of four animals. 
 
 
 
 
 
 
Figure 3. Autoradiographic visualisation of [
125
I](±)DOI binding sites in a coronal level of rat brain. (A) 
Total binding obtained with 100pM [
125
I](±)DOI. (B) Remaining non-specific binding in presence of 10 µM 
ritanserin. (C) and (D) Remaining total [
125
I](±)DOI binding in presence of 100 µM Gpp(NH)p and GTPγS 
respectively. Bar: 3 mm. 
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Figure 4. Competition curves of [
125
I](±)DOI in rat frontal cortex (upper panels), facial nucleus (medial 
panels) and choroid plexus (lower pannels) by MDL100,907 (■), ketanserin (□), SB242084 (●), and 
mesulergine (○) in absence (left panels) or presence (right panels) of 100µM Gpp(NH)p. On left panels, * 
indicates the remaining specific binding when adding 100µM Gpp(NH) in absence of competitor drugs.  
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Abbreviations 
Acb    accumbens 
ChP    choroid plexus 
Cl    claustrum 
CPu    caudate-putamen 
FCx    frontal cortex 
Tu    olfactory tubercle 
7    facial nucleus 
10     dorsal motor nucleus of vagus 
12    hypoglossal nucleus 
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Fig. 1 Saturation analysis of [125I](±)DOI binding to rat frontal cortex (A) and rat choroid plexus (B). Each 
point represents the mean specific binding of four animals.  
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Fig. 2 Inhibition curves of [125I](±)DOI binding by non-hydrolisable GTP analogues (A: Gpp(NH)p; B: GTPγS) 
in rat frontal cortex (■) and rat choroid plexus (□).Each point represents the mean of four animals.  
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Fig. 3 Autoradiographic visualisation of [125I](±)DOI binding sites in a coronal level of rat brain. (A) Total 
binding obtained with 100pM [125I](±)DOI. (B) Remaining non-specific binding in presence of 10 µM 
ritanserin. (C) and (D) Remaining total [125I](±)DOI binding in presence of 100 µM Gpp(NH)p and GTPγS 
respectively. Bar: 3 mm.  
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Fig. 4 Competition curves of [125I](±)DOI in rat frontal cortex (upper panels), facial nucleus (medial panels) 
and choroid plexus (lower pannels) by MDL100,907 (■), ketanserin (□), SB242084 (●), and mesulergine (○) 
in absence (left panels) or presence (right panels) of 100µM Gpp(NH)p. On left panels, * indicates the 
remaining specific binding when adding 100µM Gpp(NH) in absence of competitor drugs.  
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